Cardiosonic

Company Overview

Snapshot

Founded in October 2009, Cardiosonic operated with 11–50 employees, developing medical devices. The company raised $8.6 million across two funding rounds from Shmuel Almagor. A key milestone for Cardiosonic was receiving CE Mark approval for its TIVUS Ablative Catheter Device in April 2014.

Business overview

Cardiosonic specializes in developing solutions for transluminal, high-intensity ultrasound ablation within the Health Tech & Life Sciences sector. Its core product, the TIVUS high-intensity, directional ultrasound catheter system, is designed for therapeutic renal sympathetic denervation to treat resistant hypertension. This system uses ultrasound waves to ablate renal nerves, aiming to reset the body's sympathetic tone and reduce blood pressure. Cardiosonic operates in the Medical Devices and Medical Treatment & Therapeutics categories, serving healthcare providers in markets such as Europe and the United States.

Strategic signal

In April 2014, Cardiosonic received CE Mark approval for its TIVUS Ablative Catheter Device. This regulatory clearance was a significant validation for the company, indicating that its device met European safety, health, and environmental protection requirements. For investors, this signal demonstrated Cardiosonic's ability to navigate complex medical device regulations and access key markets, positioning its technology for commercialization and broader adoption in the treatment of resistant hypertension.

Company Intelligence Q&A

What is Cardiosonic's primary therapeutic focus?

Cardiosonic focuses on developing an ultrasonic energy solution for resistant hypertension, utilizing its TIVUS high-intensity, directional ultrasound catheter system for renal sympathetic denervation.

When did Cardiosonic receive CE Mark approval for its TIVUS device?

Cardiosonic received CE Mark approval for its TIVUS Ablative Catheter Device in April 2014, as reported by Business Wire.

What is the TIVUS system?

The TIVUS system, developed by Cardiosonic, consists of a catheter and a control console. It enables remote, localized, controlled, and repeatable thermal modulation of the renal vessel wall tissue to perform therapeutic renal sympathetic denervation by ultrasound ablation for resistant hypertension.

What was Cardiosonic's operational status as of July 2019?

Cardiosonic ceased to operate in July 2019, transitioning to a non-active status.